摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2S)-2-amino-3-(tert-butoxy)-1-(6-methoxypyridin-3-yl)propan-1-ol | 1196452-62-6

中文名称
——
中文别名
——
英文名称
(1R,2S)-2-amino-3-(tert-butoxy)-1-(6-methoxypyridin-3-yl)propan-1-ol
英文别名
(1R,2S)-2-amino-3-tert-butoxy-1-(6-methoxypyridin-3-yl)propan-1-ol;(1R,2S)-2-amino-1-(6-methoxypyridin-3-yl)-3-[(2-methylpropan-2-yl)oxy]propan-1-ol
(1R,2S)-2-amino-3-(tert-butoxy)-1-(6-methoxypyridin-3-yl)propan-1-ol化学式
CAS
1196452-62-6
化学式
C13H22N2O3
mdl
——
分子量
254.329
InChiKey
MLVQRXSNQANFJY-CMPLNLGQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    77.6
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Phenyl or Pyridinyl Substituted Indazoles Derivatives
    申请人:Berger Markus
    公开号:US20100080786A1
    公开(公告)日:2010-04-01
    A compound of formula Ia: The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments
    一种化学式Ia的化合物:本发明涉及新颖的吲哚啉衍生物,包括这些衍生物的制药组合物,制备这些新型衍生物的方法以及将这些衍生物用作药物的用途。
  • Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile
    作者:Lena Ripa、Karl Edman、Matthew Dearman、Goran Edenro、Ramon Hendrickx、Victoria Ullah、Hui-Fang Chang、Matti Lepistö、Dave Chapman、Stefan Geschwindner、Lisa Wissler、Petter Svanberg、Karolina Lawitz、Jesper Malmberg、Antonios Nikitidis、Roine I. Olsson、James Bird、Antoni Llinas、Tove Hegelund-Myrbäck、Markus Berger、Philip Thorne、Richard Harrison、Christian Köhler、Tomas Drmota
    DOI:10.1021/acs.jmedchem.7b01690
    日期:2018.3.8
    Synthetic glucocorticoids (GC) are essential for the treatment of a broad range of inflammatory diseases. However, their use is limited by target related adverse effects on, e.g., glucose homeostasis and bone metabolism. Starting from a nonsteroidal GR ligand (4) that is a full agonist in reporter gene assays, we exploited key functional triggers within the receptor, generating a range of structurally diverse partial agonists. Of these, only a narrow subset exhibited full anti-inflammatory efficacy and a significantly reduced impact on adverse effect markers in human cell assays compared to prednisolone. This led to the discovery of AZD9567 (15) with excellent in vivo efficacy when dosed orally in a rat model of joint inflammation. Compound 15 is currently being evaluated in clinical trials comparing the efficacy and side effect markers with those of prednisolone.
  • [EN] PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES<br/>[FR] DÉRIVÉS INDAZOLES À SUBSTITUTION PHÉNYL OU PYRIDINYLE
    申请人:ASTRAZENECA AB
    公开号:WO2009142569A1
    公开(公告)日:2009-11-26
    A compound of formula Ia: Formula (la) The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    一种化合物的化学式Ia:公式(Ia)。本发明涉及新型吲唑基衍生物,包括这种衍生物的药物组合物,制备这种新型衍生物的方法以及将这种衍生物用作药物的用途。
查看更多